Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards Psyence Biomed secures Nasdaq extension to meet compliance by December 31, advancing psilocybin-based therapeutics for mental health treatments.
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships.
Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care Psyence Biomed initiates a Phase IIb psilocybin trial in Australia to explore its potential as a treatment for Adjustment Disorder.
Psyence Biomedical (PBM) Stock Is Down 30%: What's Going On? Psyence Biomedical shares are trading lower by 34% during Wednesday's session. The company announced an exclusive licensing agreement with PsyLabs.
